-
Study Says Aubagio Lowers RRMS Relapse Rate
Relapse events dropped by roughly half over a four-year period in relapsing-remitting multiple sclerosis (RRMS) patients treated with Aubagio (teriflunomide), a real-world study reports.
The study also examined patients’ perspectives in terms of overall effectiveness, convenience, and satisfaction with the use of Aubagio. Learn more about the study and its findings here.
Do you take or have you considered taking Aubagio?
-
0 Replies
Sorry, there were no replies found.
Log in to reply.